Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics.
about
Rationale for the Successful Management of EDTA Chelation Therapy in Human Burden by Toxic MetalsAndrographolide induces Nrf2 and heme oxygenase 1 in astrocytes by activating p38 MAPK and ERKIron-Restricted Diet Affects Brain Ferritin Levels, Dopamine Metabolism and Cellular Prion Protein in a Region-Specific Manner.Biomonitorization of iron accumulation in the substantia nigra from Lewy body disease patients.Post translational changes to α-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson's disease.The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's diseaseDefining a role for hemoglobin in Parkinson's diseaseSpecific Binding of Cu(II) Ions to Amyloid-Beta Peptides Bound to Aggregation-Inhibiting Molecules or SDS Micelles Creates Complexes that Generate Radical Oxygen Species.Whole-brain metallomic analysis of the common marmoset (Callithrix jacchus).Enhanced Histochemical Detection of Iron in Paraffin Sections of Mouse Central Nervous System Tissue: Application in the APP/PS1 Mouse Model of Alzheimer's Disease.The Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune EncephalomyelitisMetalloneurochemistry and the Pierian Spring: 'Shallow Draughts Intoxicate the Brain'.New Insights into the Crosstalk between NMDARs and Iron: Implications for Understanding Pathology of Neurological Diseases.Neuropathology of suicide: recent findings and future directions.Alpha-synuclein: relating metals to structure, function and inhibition.Oxidative stress-induced CREB upregulation promotes DNA damage repair prior to neuronal cell death protection.Iron and dopamine: a toxic couple.'From past to future' - deciphering the molecular basis of Alzheimer's disease through the pages of the Journal of Neurochemistry.199 years of Parkinson disease - what have we learned and what is the path to the future?One protein, multiple pathologies: multifaceted involvement of amyloid β in neurodegenerative disorders of the brain and retina.The Complex Role of Apolipoprotein E in Alzheimer's Disease: an Overview and Update.Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care.Amyloid plaques beyond Aβ: a survey of the diverse modulators of amyloid aggregation.Elevated plasma ferritin in elderly individuals with high neocortical amyloid-β load.Restless legs syndrome in Parkinson disease: Clinical characteristics, abnormal iron metabolism and altered neurotransmitters.Trehalose Improves Cognition in the Transgenic Tg2576 Mouse Model of Alzheimer's Disease.Transport of Non-Transferrin Bound Iron to the Brain: Implications for Alzheimer's Disease.Mutual interference of Cu and Zn ions in Alzheimer's disease: perspectives at the molecular level.Impairment of Hepcidin Upregulation by Lipopolysaccharide in the Interleukin-6 Knockout Mouse Brain.Cell Death Pathways: a Novel Therapeutic Approach for Neuroscientists.Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease.Development of an iron-selective antioxidant probe with protective effects on neuronal function.No Genetic Overlap Between Circulating Iron Levels and Alzheimer's Disease.Effect of sub-chronic ferrous sulfate treatment on motor skills, hematological and biochemical parameters in rats.Thalamic alterations remote to infarct appear as focal iron accumulation and impact clinical outcome.Subnanomolar indazole-5-carboxamide inhibitors of monoamine oxidase B (MAO-B) continued: indications of iron binding, experimental evidence for optimised solubility and brain penetration.MR imaging differentiation of Fe2+ and Fe3+ based on relaxation and magnetic susceptibility properties.Structural and Mechanistic Insights into Development of Chemical Tools to Control Individual and Inter-Related Pathological Features in Alzheimer's Disease.Loss of NCB5OR in the cerebellum disturbs iron pathways, potentiates behavioral abnormalities, and exacerbates harmaline-induced tremor in mice.Hepcidin, an emerging and important player in brain iron homeostasis.
P2860
Q28073733-E5520379-74BE-4F40-9656-AB5B2986B0B6Q28389948-2385F293-ED37-42FC-B323-5611B76C5047Q33695111-532BED8B-699C-4DE2-B034-76F61306C8A4Q33703477-BDFD5672-17AD-4C07-8654-0591CAA6B521Q33776138-3F8E4E5C-CDE3-4C72-B787-5590D50CE063Q33850971-FA0EEFFF-9FDD-4E10-BFCD-64F21097690FQ33917264-3DD37F96-6C12-425D-9260-342726277B12Q36115161-D09FD3EC-ACF5-4F4A-9EC7-A3CFD00163FCQ36293352-CB111F64-C9E6-4594-BB66-CCB7D0BB1B26Q37299284-797191C3-0384-4A78-883A-B0916F171106Q37333860-7D1ADAD0-004B-4CFA-BEFA-04711C8D6F14Q37634339-31C89E46-B709-41F0-976D-311E634CAFCBQ37703489-7E5CEFA6-95D3-4ACC-8FA2-B363224C89FCQ38659366-82FB29BD-1D10-43FE-AA82-EF798CB6B7ACQ38728563-A365A910-D7A2-42F1-A603-3576AF58B94FQ38732714-CEA2D0F0-3F8C-4AC2-9514-DBB469F3DC9BQ38768061-553BEAA3-B18F-4F5E-8746-8CFCFB3A074BQ38782451-61E791F9-8AE0-43B1-A7D8-2C3E79D7E1B5Q38825770-FD907F94-8E76-4E28-A4D8-8BC3EFF56502Q38873518-BE48C9F9-C1AE-418F-A6FB-DEFDD7840A7FQ38959290-635C0FAE-5DCB-4709-B58F-E740FB6928E5Q39179797-DC1EA779-6EE0-4EC5-8264-BC73BFCE6946Q39385143-3DA821E6-D42A-49B3-8738-CA8DFD606321Q40139851-8A266C2D-7084-4E96-95FC-C86736CDF80CQ41620070-BA51471C-8259-4242-93DB-E4FDD2484EA5Q41852404-630FACCB-DFF4-4380-A717-B3EA2C2B19DCQ42261227-A934B4E5-940F-4A2A-A26D-7928E4D778EBQ45327210-37262D33-139E-47A0-800F-5E6846F023DDQ45833819-E9BE16BF-5A17-4387-A743-7E42E59DB828Q46279808-A197CB71-0FA9-4371-BC87-1678E6B19359Q46292537-2E778AE5-E759-44E9-B534-0215FB8EFE95Q47130659-CBE637F3-5E9F-4A70-9CCA-09C8B0425EDCQ47703297-52B18FC1-779D-47BE-8B7A-B3E2DE3AA76EQ47826692-618FA222-56DE-48D6-AF0C-C8DFCED237A6Q47875056-E2E09F68-AA08-420D-91CA-E668500A0840Q47964614-237781F2-3BF3-4D0E-93F6-51AEB9FF2FACQ48097181-581074AF-296E-4DF0-A9E2-199A64B30917Q48125467-19029F85-16D8-48B7-A436-73EAA28B10BBQ48730588-7349C8DE-C243-4EFA-BF41-23F26CC40648Q49885816-ED4AF7CC-4FF8-477E-9D79-D0A9328AA35A
P2860
Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Iron neurochemistry in Alzheim ...... ase: targets for therapeutics.
@en
type
label
Iron neurochemistry in Alzheim ...... ase: targets for therapeutics.
@en
prefLabel
Iron neurochemistry in Alzheim ...... ase: targets for therapeutics.
@en
P2860
P356
P1476
Iron neurochemistry in Alzheim ...... ase: targets for therapeutics.
@en
P2860
P304
P356
10.1111/JNC.13425
P407
P478
139 Suppl 1
P577
2015-11-06T00:00:00Z